The expanding role of blood and tissue establishments in the development of advanced therapy medicinal products

被引:1
|
作者
Horan, Aisling [1 ]
Warreth, Shada [2 ,3 ]
Hervig, Tor [1 ,4 ]
Waters, Allison [1 ,5 ]
机构
[1] Natl Blood Ctr, Irish Blood Transfus Serv, Jamess St, Dublin D08 NH5R, Ireland
[2] Technol Univ Dublin, Sch Chem & Pharmaceut Sci, Dublin, Ireland
[3] Natl Inst Bioproc Res & Training NIBRT, Belfield, Dublin, Ireland
[4] Trinity Coll Dublin, Sch Med, Dublin, Ireland
[5] Univ Coll Dublin, UCD Sch Publ Hlth Physiotherapy & Social Sci, Dublin, Ireland
关键词
advanced therapeutic medicinal products; ATMP; blood establishment; cellular therapy; GMP; Good Manufacturing Practice; Introduction;
D O I
10.1016/j.jcyt.2024.02.012
中图分类号
Q813 [细胞工程];
学科分类号
摘要
Background aims: The relationship between blood establishments and advanced cellular therapies is evident in several European countries, with some involved in research and development and/or in manufacturing. The aim of the present study was to understand the advanced therapy medicinal product (ATMP) infrastructural, regulatory and logistic requirements needed for the Irish Blood Transfusion Service to support advanced therapeutics in Ireland. Methods: An online survey consisting of 13 questions was distributed in a targeted manner to the identi fied ATMP stakeholders in Ireland, namely those working in industry, health care, regulatory agencies or education. Subject matter experts in the field were approached and interviewed to gain further insight into the relationship between blood and tissue establishments (BTEs) and ATMPs, to explore the advantages these institutions have in development and to highlight potential challenges for implementation. Results: In total, 84.9% of survey respondents stated that BTEs have a role in the development of advanced therapeutics. Key BTE services identi fied as applicable to the ATMP sector from both surveys and interviews include the provision of starting materials for research and manufacturing, donor management, use of existing quality and traceability frameworks, product logistic strategies and Good Manufacturing Practice. Challenges for BTE expansion into the sector currently include high costs associated with ATMPs, lack of expertise in these therapies, limited therapeutic populations and no national ATMP strategic plan for Ireland. Conclusions: Blood establishments have services and expertise that can be extended into the advanced therapy sector. The existing knowledge and skill base of BTEs in Ireland should be leveraged to accelerate the development of ATMP strategies for industry and healthcare. (c) 2024 International Society for Cell & Gene Therapy. Published by Elsevier Inc. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/)
引用
收藏
页码:524 / 530
页数:7
相关论文
共 32 条
  • [21] Bringing Advanced Therapy Medicinal Products (ATMPs) for Parkinson's Disease to the Clinic: The Investigator's Perspective
    Barker, Roger A.
    Cutting, Emma, V
    Daft, Danielle M.
    JOURNAL OF PARKINSONS DISEASE, 2021, 11 : S129 - S134
  • [22] Advanced Therapy Medicinal Products: How to Bring Cell-Based Medicinal Products Successfully to the Market - Report from the CAT-DGTI-GSCN Workshop at the DGTI Annual Meeting 2014
    Celis, Patrick
    Ferry, Nicolas
    Hystad, Marit
    Schuessler-Lenz, Martina
    Doevendans, Pieter A.
    Flory, Egbert
    Beuneu, Claire
    Reischl, Ilona
    Salmikangas, Paula
    TRANSFUSION MEDICINE AND HEMOTHERAPY, 2015, 42 (03) : 196 - 201
  • [23] Unlocking the value of innovative medicines: Insights from the advanced therapy medicinal products (ATMP) innovation systems in Germany and Sweden
    Fischer, Piret
    Reiss, Thomas
    Mahlich, Jorg
    Gicquel, Erwan
    Aichinger, Heike
    Pullmann, Liliya
    Bratan, Tanja
    HEALTH POLICY AND TECHNOLOGY, 2023, 12 (02)
  • [24] Requirements for long-term follow-up on efficacy and safety of advanced therapy medicinal products. Risk management and traceability
    Klug, B.
    Reinhardt, J.
    Schroeder, C.
    BUNDESGESUNDHEITSBLATT-GESUNDHEITSFORSCHUNG-GESUNDHEITSSCHUTZ, 2010, 53 (01) : 58 - 62
  • [25] Call for More Effective Regulation of Clinical Trials with Advanced Therapy Medicinal Products Consisting of or Containing Genetically Modified Organisms in the European Union
    Beattie, Stuart
    HUMAN GENE THERAPY, 2021, 32 (19-20) : 997 - 1003
  • [26] Process development and validation of expanded regulatory T cells for prospective applications: an example of manufacturing a personalized advanced therapy medicinal product
    Cristiana Lavazza
    Silvia Budelli
    Elisa Montelatici
    Mariele Viganò
    Francesca Ulbar
    Lucia Catani
    Marta Giulia Cannone
    Sara Savelli
    Elisa Groppelli
    Lorenza Lazzari
    Roberto M. Lemoli
    Matteo Cescon
    Gaetano La Manna
    Rosaria Giordano
    Tiziana Montemurro
    Journal of Translational Medicine, 20
  • [27] Process development and validation of expanded regulatory T cells for prospective applications: an example of manufacturing a personalized advanced therapy medicinal product
    Lavazza, Cristiana
    Budelli, Silvia
    Montelatici, Elisa
    Vigano, Mariele
    Ulbar, Francesca
    Catani, Lucia
    Cannone, Marta Giulia
    Savelli, Sara
    Groppelli, Elisa
    Lazzari, Lorenza
    Lemoli, Roberto M.
    Cescon, Matteo
    La Manna, Gaetano
    Giordano, Rosaria
    Montemurro, Tiziana
    JOURNAL OF TRANSLATIONAL MEDICINE, 2022, 20 (01)
  • [28] Development of a human umbilical cord-derived mesenchymal stromal cell-based advanced therapy medicinal product to treat immune and/or inflammatory diseases
    Mebarki, Miryam
    Iglicki, Nathan
    Marigny, Celine
    Abadie, Camille
    Nicolet, Claire
    Churlaud, Guillaume
    Maheux, Camille
    Boucher, Helene
    Monsel, Antoine
    Menasche, Philippe
    Larghero, Jerome
    Faivre, Lionel
    Cras, Audrey
    STEM CELL RESEARCH & THERAPY, 2021, 12 (01)
  • [29] Development of a human umbilical cord-derived mesenchymal stromal cell-based advanced therapy medicinal product to treat immune and/or inflammatory diseases
    Miryam Mebarki
    Nathan Iglicki
    Céline Marigny
    Camille Abadie
    Claire Nicolet
    Guillaume Churlaud
    Camille Maheux
    Hélène Boucher
    Antoine Monsel
    Philippe Menasché
    Jérôme Larghero
    Lionel Faivre
    Audrey Cras
    Stem Cell Research & Therapy, 12
  • [30] Potenzial hämatopoetischer Stammzellen als Ausgangsmaterial für Arzneimittel für neuartige TherapienPotential of hematopoietic stem cells as the basis for generation of advanced therapy medicinal products
    H. Bönig
    M. Heiden
    J. Schüttrumpf
    M.M. Müller
    E. Seifried
    Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz, 2011, 54 (7) : 791 - 796